Pink Sheet reporter reviews recent stories on US FDA concerns about the EU data protection regulation, the US enacting the Medicare price negotiation law, warning letters sent to Emergent BioSolutions and ImprimisRx, and Amylyx’s ALS drug going in front of the Institute for Clinical and Economic Review.